ArticleOncology letters2016
Ras protein expression as a marker for breast cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Elevated FBXL6 activates both wild-type KRAS and mutant KRASMilitary Medical Research · 2023Trial
- The Urinary Proteome Differs with the Presence and Type of Breast Cancer.Journal of proteome research · 2025Article
- Review
- Alkaloid fraction of Achyranthes aspera Linn triggers breast cancer apoptosis in mice (Open veterinary journal · 2025Article
- Effects of Curcumin and Estrogen Receptor Alpha in Luminal Breast Cancer Cells.Diagnostics (Basel, Switzerland) · 2024Article
- Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review).Oncology reports · 2021Article
- Acetic Acid and Iodine Staining for Determining Malignancy in Solid Tumors.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Curcumin rescues breast cells from epithelial‑mesenchymal transition and invasion induced by anti‑miR‑34a.International journal of oncology · 2020Article
- Article
- Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer.Open access Macedonian journal of medical sciences · 2019Article
- WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, the most common neoplasm in women of all ages, is the leading cause of cancer-related mortality in women worldwide. Markers to help to predict the risk of progression and ultimately provide non-surgical treatment options would be of great benefit. At present, there are no available molecular markers to predict the risk of carcinoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.